Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

2.440 +0.050 (+2.09%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NRX Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Eliminates Balance Sheet Debt Through Anson Equity Conversion
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
More Than 1 Million Suicidal Depression Cases Per Year May Be Treated by 2030 via New Indication for Augmentation of Transcranial Magnetic Stimulation: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment
Via Investor Brand Network
News headline image
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
FDA Submission for Abbreviated New Drug Application; $750 Million Market for Suicidal Depression Market Awaits Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date
Via Investor Brand Network
NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Schedules Corporate Update Call for Dec. 2
Via Investor Brand Network
News headline image
NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at NobleCon21
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
New to The Street Show #702 Airs Today on Bloomberg at 6:30 PM EST
Via ACCESS Newswire
News headline image
Three Revenue-Generating Facilities in Florida Plus Six More by Year-End in Expanding $750 Million Market Suicidal Depression Market: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q3 Results and Advances NRX-100 and NRX-101 Regulatory Programs
Via Investor Brand Network
News headline image
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Q3 2025 Financial Results and Host Conference Call on Nov. 17
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances Toward Completion
Via Investor Brand Network
News headline image
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
$750 Million Market On Track to $3.35 Billion by 2034 Has High Return Opportunity with First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health: NRXP
Via Get News
MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Launches HOPE Therapeutics’ One-Day TMS Protocol for Treatment-Resistant Depression in Florida
Via Investor Brand Network
News headline image
HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
InvestorNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Advancing Two-Pronged Approach to Bring Innovative Therapies to Market
Via Investor Brand Network
News headline image
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
MissionIRNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Advances KETAFREE(TM), Expands Pipeline Targeting Urgent Needs
Via Investor Brand Network
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies
Via Investor Brand Network
News headline image
New to The Street Broadcasts Tonight on Bloomberg Featuring Roadzen, Metaterra, NRx Pharma, Blackbarn NYC, and Humanitarian Travel Group
Via ACCESS Newswire
BioMedNewsBreaks — NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Strengthens Pipeline with Dual Pathways for Ketamine-Based Therapies
Via Investor Brand Network
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition
Via Investor Brand Network
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
Via Investor Brand Network
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.